CME
This activity is jointly provided by Partners for Advancing Clinical Education (PACE), and DKBmed. This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Enduring internet activity
Estimated time to complete this activity: 60 minutes
There is no fee for this educational activity.
Program release: May 1, 2024
Program expires: May 1, 2026
For CME questions, please visit https://partnersed.com/.
Target Audience
The target audience includes primary care clinicians and other clinicians involved in the care of patients with diabetes.
Learner Outcomes
After completing this activity, the participant should be better able to:
- Explain the pathophysiology of diabetic retinopathy (DR) and the importance of early screening for DR
- Describe the benefits of current treatment options for DR/DME, including VEGF inhibitors
- Describe and use available retina screening devices with and without AI to ensure compliance with ADA/AAO guidelines for regular screening of all patients with T2DM
Faculty
Rishi P. Singh, MD, FASRS
Vice President/Chief Medical Officer of Martin North and South Hospitals
Professor of Ophthalmology, Cleveland Clinic Lerner College of Medicine
Cleveland Clinic Martin Health
Surendra Khera, MD, MSc
Vice Chief of Primary Care, Cleveland Clinic Florida
President, Cleveland Clinic Florida Integrated Health
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and DKBmed LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this nursing continuing professional development activity is 1.0 contact hours. This 1.0 contact hour NCPD activity is provided by the Institute for Johns Hopkins Nursing. Statements will be awarded for this educational activity until May 1, 2025
Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
Disclosure of Conflicts of Interest
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
Faculty / Presenter Reported Financial Relationship
Rishi P. Singh, MD, FASRS
Vice President/Chief Medical Officer of Martin North and South Hospitals
Professor of Ophthalmology, Cleveland Clinic Lerner College of Medicine
Cleveland Clinic Martin Health
- Consultant, Advisor, Speaker: Alcon, Allergan/Abbvie, Apellis, Eyepoint, Iveric, Genentech/Roche, Regeneron Pharmaceuticals, Inc., Zeiss
Surendra Khera, MD, MSc
Vice Chief of Primary Care, Cleveland Clinic Florida
President, Cleveland Clinic Florida Integrated Health
- None
Planners and Managers
The PACE planners and managers have nothing to disclose. The DKBmed planners and managers have nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of the IJHN name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.
Request for Credit/Fees
There are no fees for participating and receiving CME contact hours credit for this activity. During the period of May 1, 2024 through May 1, 2025, participants must read the learning objectives and faculty disclosures and study the educational activity. In order to receive nursing contact hours, participants must also complete and submit an evaluation. If you wish to receive acknowledgment for completing this activity, please complete the evaluation.
Hardware/Software Requirements
Include minimum hardware, software, internet connectivity and connection speed requirements for accessing the internet-based activity.